Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Sangamo Therapeutics Inc.

    NASDAQ: SGMO · Real-Time Price · USD
    0.54
    -0.02 (-3.10%)
    At close: Jun 27, 2025, 3:59 PM
    0.54
    -1.11%
    After-hours: Jun 27, 2025, 05:44 PM EDT
    -3.10%
    Bid 0.53
    Market Cap 132.89M
    Revenue (ttm) 63.76M
    Net Income (ttm) -79.45M
    EPS (ttm) -0.36
    PE Ratio (ttm) -1.5
    Forward PE -1.6
    Analyst Buy
    Ask 0.55
    Volume 3,080,108
    Avg. Volume (20D) 7,190,948
    Open 0.56
    Previous Close 0.56
    Day's Range 0.53 - 0.57
    52-Week Range 0.30 - 3.18
    Beta 1.21

    About SGMO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SGMO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SGMO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Sangamo Therapeutics Inc. is scheduled to release its earnings on Aug 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    -38.4%
    Sangamo Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
    2 months ago
    -4.73%
    Sangamo Therapeutics shares are trading higher after the company announced it entered a capsid license agreement with Lilly.
    news image

    3 days ago · businesswire.com

    Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

    RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease.

    news image

    1 month ago · seekingalpha.com

    Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q1 2025 Earnings Conference Call May 12, 2025 6:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications ...

    news image

    1 month ago · zacks.com

    Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

    Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.27 per share a year ago.

    news image

    1 month ago · businesswire.com

    Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

    RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results.

    news image

    1 month ago · businesswire.com

    Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

    RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering.

    news image

    1 month ago · businesswire.com

    Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

    RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 EARNINGS CALL.

    news image

    1 month ago · businesswire.com

    Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

    RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease.

    news image

    1 month ago · zacks.com

    Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · businesswire.com

    Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

    RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS TO PRESENT NEUROLOGY PIPELINE ADVANCES AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT).

    news image

    2 months ago · seekingalpha.com

    Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

    Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payme...

    Add to Watchlist